News

Ophthalmology Times1d
Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis
Krystal Biotech announced the first patient has been dosed in EMERALD-1, its phase 1/2 clinical trial evaluating KB801 for ...
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.